Guangzhou Xinji Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinji Medical") has recently submitted a second prospectus to the Hong Kong Stock Exchange, aiming to list on the main board under Chapter 18A rules. The company specializes in two key drug delivery technology platforms: soluble microneedles and nasal inhalation. Its core products are still in Phase II clinical trials, with no commercialized products yet. A review of the prospectus and related documents reveals that Xinji Medical's IPO path is far from smooth. During the reporting period, the company accumulated losses exceeding 450 million yuan, with gross margins for its core business declining. Both of its two core products remain in early clinical stages, posing significant uncertainty around their technological pathways and commercial prospects. Additionally, a highly concentrated family-owned equity structure, multiple shell subsidiaries, and regulatory inquiries into potential conflicts of interest highlight governance and internal control issues that cannot be overlooked.
Persistent Deep Losses and Significant Cash Flow Strain Amidst a Crowded Competitive Landscape
From a financial perspective, the prospectus data shows that for the years 2024, 2025, and the first five months of 2026, the company generated revenues of 49.026 million yuan, 55.238 million yuan, and 16.567 million yuan, respectively. Corresponding net losses were 147 million yuan, 111 million yuan, and 197 million yuan, bringing cumulative losses to 455 million yuan. Notably, the loss for just the first five months of 2026 was nearly 1.8 times the full-year loss of 2025, indicating an accelerating loss trend. In terms of revenue structure, Xinji Medical's current income is entirely derived from its CRO research and development services and MAH licensing business, neither of which is its core innovative drug business, and both are experiencing declining profitability and revenue scale. From 2024 to the first five months of 2026, the company's overall gross margin fell from 33.7% to 23.4%, and further to 19.8%, a decline of nearly 14 percentage points over two years. Specifically, CRO service revenue dropped from 46.348 million yuan in 2024 to 41.856 million yuan in 2025; in the first five months of 2026, this segment generated 12.402 million yuan, a year-on-year decline of approximately 20%. The MAH business also showed weakness, with revenue of 4.165 million yuan in the first five months of 2026, down 29.05% year-on-year. Regarding gross margins, the MAH business's gross margin fell from 8.0% in 2024 to 5.8% in May 2026, while the CRO service's gross margin dropped from 35.2% in 2024 to 24.5% in May 2026. On the balance sheet side, as of the end of May 2026, Xinji Medical had total assets of approximately 209 million yuan and total liabilities of 740 million yuan, resulting in a debt-to-asset ratio of 354%. As of May 31, 2026, the company's net current liabilities still stood at 573 million yuan, with a current ratio of only 0.2, indicating weak short-term solvency. In terms of cash reserves, the company held only 102.6 million yuan in cash and cash equivalents as of May 31, 2026. Based on current cash burn rates, existing funds can sustain operations for only about eight months.
From a business perspective, Xinji Medical primarily focuses on formulating improved versions of already approved active ingredients. While the R&D risk is lower compared to developing entirely new drug targets, it faces challenges such as limited clinical value, a crowded competitive landscape, and weak pricing power. Currently, the company has two core products in development: a dexmedetomidine hydrochloride microneedle patch (DHMP) and a Parkinson's disease nasal spray, XJN010, along with three other pipeline products in earlier stages. Among these, DHMP is Xinji Medical's most prominent product, positioned for preoperative sedation in children and adults. It is also the only soluble microneedle drug patch in China to have entered Phase II clinical trials. The product's Phase IIa clinical trial for pediatric indications began in August 2025 and was completed in June 2026. The Phase II clinical trial for adult indications started in March 2026, and a Phase I clinical trial in the US is planned for the fourth quarter of 2026. The prospectus highlights that DHMP's microneedle delivery offers advantages like being painless and convenient. However, this technological pathway has several unverified clinical risks. A key issue is drug loading limitations, as soluble microneedles generally have low drug-carrying capacity. It remains to be validated by data whether dexmedetomidine, a potent sedative, can achieve the required blood concentration and depth of sedation via the microneedle route. Additionally, intravenous dexmedetomidine is already widely used clinically, is inexpensive, and is covered by medical insurance. In a hospital setting for preoperative sedation, intravenous administration is performed by medical staff. Patient willingness to pay a premium for a painless alternative may be limited, questioning whether the microneedle formulation can command a significant price premium. XJN010 is a nasal inhalation formulation for Parkinson's disease, with its Phase II clinical trial starting in August 2025 and completing in April 2026. However, this area already has similar products on the market, such as esktamine inhalation powder. The nasal route also faces technical challenges, including unstable delivery efficiency, nasal mucosal damage, and patient compliance issues. Historically, several similar nasal delivery products have been discontinued due to poor efficacy or safety problems, including those for davanite, fasudil nasal spray, and epinastine nasal spray. XJN010's Phase II data has not yet been released, and its clinical value remains to be proven.
Family Absolute Control: Shell Subsidiaries and Regulatory Inquiry into Conflicts of Interest
Beyond financial and R&D risks, Xinji Medical also harbors governance concerns. The equity structure reveals a highly concentrated family control. Founder Dr. Wu Chuanbin and his spouse, Dr. Pan Xin, together control 51.01% of the company's shares through direct holdings and several investment platforms such as Shanji Investment, Deji Investment, and Minji Investment, giving them absolute control. This family influence is particularly evident in the composition of management and the board of directors. Of the three executive directors, besides Wu Chuanbin himself serving as Chairman and CEO, the other two, Jia Lu and Yang Beibei, are nieces of Wu and Pan, serving as Assistant Financial Director and Director of the Microneedle Formulation R&D Center, respectively. Among the non-executive directors, Pan Xin, as Wu's spouse and a professor at Sun Yat-sen University's School of Pharmacy, participates in major board decisions. With key positions, especially in finance and R&D, filled by family members, the independence and checks and balances of corporate governance are potentially compromised. Furthermore, a major drawback of family governance is the risk of related-party transactions and conflicts of interest. In its supplementary material requirements for overseas issuance and listing filings, the China Securities Regulatory Commission (CSRC) explicitly requested that the company provide a conclusion on whether the share prices of new shareholders added in the past 12 months are fair and whether there are any conflicts of interest. It also required a review of the legality and compliance of employee equity incentives, as well as the relationship between participants and the company's directors, supervisors, and senior management. Anomalies at the subsidiary level have also drawn regulatory attention. The CSRC required the company to explain the reasons and reasonableness behind four of its seven subsidiaries having no substantive business activities. The existence of multiple shell subsidiaries is often seen as a potential vehicle for financial adjustments, related-party transactions, or fund transfers. This is particularly concerning for a company with high debt ratios and tight cash flow, raising questions about the transparency and necessity of its multi-layered subsidiary structure.
In summary, while Xinji Medical has nearly two decades of experience in improved new drugs and two conceptually attractive technology platforms, it faces significant challenges across its financial performance, R&D pipeline, and corporate governance. With no near-term prospect of commercialization and a growing funding gap, the company's ability to successfully navigate the capital markets remains highly uncertain.
Comments